FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Khuda Dad Khan

Research Profile

Concepts & Ideas

Chemicals & Drugs

Procedures

Remission Induction

Disorders

Co-author Network

Publications

TOP 3
Stephen M Ansell; Steven Horwitz; Andreas Engert; Khuda Dad Khan; Thomas Lin; Roger K Strair; Tibor Keler; Robert F Graziano; Diann Blanset; Michael Yellin; Steven Fischkoff; Albert Assad; Peter Borchmann
Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma.
Francis Giles; David A Rizzieri; Judith E Karp; Norbert Vey; Farhad Ravandi; Stefan Faderl; Khuda Dad Khan; Gregor Verhoef; Pierre W Wijermans; Anjali Advani; Gail J Roboz; Andrew Lamb; Syed Fazl Ali Bilgrami; Augustin Ferrant; S M G J Daenen; Verena Karsten; Ann Cahill; Maher Albitar; Ghulam Mufti; Susan O'Brien
Cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients age 60 years or older with previously untreated acute myeloid leukemia.
Khuda Dad Khan; Christos Emmanouilides; Don M Benson; Deborah Hurst; Pablo Garcia; Glenn Michelson; Sandra Milan; Amy K Ferketich; Lawrence Piro; John P Leonard; Pierluigi Porcu; Charles F Eisenbeis; Amy L Banks; Lei Chen; John C Byrd; Michael A Caligiuri
A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Khuda Dad Khan (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2007: Stephen M Ansell; Steven Horwitz; Andreas Engert; Khuda Dad Khan; Thomas Lin; Roger K Strair; Tibor Keler; Robert F Graziano; Diann Blanset; Michael Yellin; Steven Fischkoff; Albert Assad; Peter Borchmann
Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(19):2764-9.
2007: Francis Giles; David A Rizzieri; Judith E Karp; Norbert Vey; Farhad Ravandi; Stefan Faderl; Khuda Dad Khan; Gregor Verhoef; Pierre W Wijermans; Anjali Advani; Gail J Roboz; Andrew Lamb; Syed Fazl Ali Bilgrami; Augustin Ferrant; S M G J Daenen; Verena Karsten; Ann Cahill; Maher Albitar; Ghulam Mufti; Susan O'Brien
Cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients age 60 years or older with previously untreated acute myeloid leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(1):25-31.
2006: Khuda Dad Khan; Christos Emmanouilides; Don M Benson; Deborah Hurst; Pablo Garcia; Glenn Michelson; Sandra Milan; Amy K Ferketich; Lawrence Piro; John P Leonard; Pierluigi Porcu; Charles F Eisenbeis; Amy L Banks; Lei Chen; John C Byrd; Michael A Caligiuri
A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(23):7046-53.
2006: Francis Giles; Srdan Verstovsek; Stefan Faderl; Norbert Vey; Judith E Karp; Gail J Roboz; Khuda Dad Khan; Maureen Cooper; Syed Fazl Ali Bilgrami; Augustin Ferrant; S M G J Daenen; Verena Karsten; Ann Cahill; Maher Albitar; Andrew Lamb; Susan O'Brien; Eric Feldman
A phase II study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients with very high risk relapsed acute myeloid leukemia.
Leukemia research 2006;30(12):1591-5.
2006: Ronald Halbert; Robert A Figlin; Michael B Atkins; Myriam Bernal; Thomas E Hutson; Robert G Uzzo; Ronald M Bukowski; Khuda Dad Khan; Christopher G Wood; Robert W Dubois
Treatment of patients with metastatic renal cell cancer: a RAND Appropriateness Panel.
Cancer 2006;107(10):2375-83.
2003: Francis Giles; Maureen A Cooper; Lewis Silverman; Judith E Karp; Jeffrey E Lancet; Maurizio Zangari; Paul J Shami; Khuda Dad Khan; Alison L Hannah; Julie M Cherrington; Deborah A Thomas; Guillermo Garcia-Manero; Maher Albitar; Hagop M Kantarjian; Alison T Stopeck
Phase II study of SU5416--a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor--in patients with refractory myeloproliferative diseases.
Cancer 2003;97(8):1920-8.